Molecular Templates, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Molecular Templates reports a net loss for Q2 2024 and expresses substantial doubt about its ability to continue as a going concern.
Molecular Templates reports a net income of $572,000 for Q1 2024, while navigating the termination of the Bristol-Myers Squibb collaboration and implementing cost-saving measures.